Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

NOVO-NORDISK A/S-SPONS ADR

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Siegen,,North,Rhine,Westphalia,,,Germany,-,10,11,2023:

Biotech

Large Cap

News

Health Care

General

España investiga a Novo Nordisk por publicidad encubierta, mientras Reino Unido estudia factores genéticos en riesgos de medicamentos GLP-1.

Novo Nordisk bajo investigación:riesgos genéticos y posible publicidad encubierta en España

Medical,Billing,Document,And,Dollar,Banknote,,Calculator,,Stathoscope.,Medical,Treatment

Markets

AMGN

REGN

RHHBY

Trump anuncia una orden ejecutiva para reducir precios de medicamentos hasta un 80 %, aplicando la política de &#34;Nación Más Favorecida&#34;.

Trump firma orden ejecutiva histórica para reducir precios de medicamentos en EE. UU.

Equities

Novo Nordisk revisa a la baja sus previsiones de crecimiento para 2025 debido a la competencia de versiones compuestas de GLP-1 en EE. UU.

Novo Nordisk (NVO) reduce previsiones de ventas 2025 por competencia de versiones compuestas

Novo Nordisk AS

Precidian ETFs Trust Novo Nordisk A/S B Shares ADRhedged

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

Against a backdrop of regulatory scrutiny, with Spain investigating Novo Nordisk for alleged covert advertising of its popular weight-loss drugs, the U.K. is initiating research to determine if genetic factors impact the risk of acute pancreatitis associated with GLP-1 injections.
Yellow Card Biobank, a collaboration between the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England, will start investigating whether the risk of acute pancreatitis (inflamed pancreas) from GLP-1 injections for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">weight loss and Type 2 diabetes</a> may be influenced by an individual&#8217;s genes.
The agency <a target="_blank" href="https://www.gov.uk/government/news/if-you-take-a-glp-1-medicine-and-have-been-hospitalised-by-acute-pancreatitis-the-yellow-card-biobank-wants-to-hear-from-you" rel="noreferrer noopener">said</a> in a statement on Thursday that although infrequent, acute pancreatitis has been reported with GLP-1 medicines.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46102213/us-adults-struggle-with-long-term-use-of-obesity-drugs-like-wegovy-data-shows" rel="noreferrer noopener">US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows</a>
Patients hospitalized with <a href="https://www.benzinga.com/general/biotech/23/10/35123873/novo-nordisks-weight-loss-drugs-like-wegovy-ozempic-may-pose-serious-stomach-risks-study-suggests" target="_blank" rel="noreferrer noopener">acute pancreatitis suspected </a>to be related to glucagon-like peptide-1 receptor agonists (GLP-1 medicines), such as Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic (semaglutide) and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro (Tirzepatide), are asked to report it to the MHRA&#8217;s&nbsp;Yellow Card scheme.
These medicines are sometimes referred to colloquially as &#8220;skinny jabs,&#8221; although they are licensed for both weight loss and Type 2 diabetes.&nbsp;
Healthcare professionals are also being asked to help recruit for the study by reporting Yellow Cards on behalf of patients experiencing acute pancreatitis while taking GLP-1 medicines.&nbsp;
When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to participate in the Biobank study.
This would involve providing further information and submitting a saliva or spit sample, which will be used to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genetic makeup.
Dr Alison Cave, MHRA Chief Safety Officer, said, &#8220;Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing. It is predicted that adverse drug reactions cost the NHS more than 2.2 billion pounds ($3.02 billion) a year in hospital stays alone.&#8221;
On June 19, Spain&#8217;s Ministry of Health, through the General Directorate of the Common Portfolio of Services of the National Health System (NHS) and Pharmacy, requested information from Novo Nordisk Pharma after detecting indications that one of its information portals may be <a href="https://www.bmj.com/content/389/bmj.r1319" target="_blank" rel="noreferrer noopener">violating</a> regulations regarding drug advertising.
The initiative follows a media report <a target="_blank" href="https://www.sanidad.gob.es/en/gabinete/notasPrensa.do?id=6699" rel="noreferrer noopener">about</a> a website, which redirects to another page called &#8220;Obesity without filters,&#8221; managed by the laboratory. It presents informative content related to the approach to obesity, including images expressly indicating that this is a Novo Nordisk initiative endorsed by various scientific societies.
The Ministry has formally requested that the company provide documentation regarding the endorsement declared by these scientific and professional organizations.
It has also drawn attention to another link on the website containing recommended questions for the doctor. Although no pharmacological treatment is explicitly mentioned, the Ministry believes that the content could constitute indirect advertising for prescription drugs, the public promotion of which is prohibited under current legislation.
Meanwhile, Novo Nordisk continues the expansion of patient access to Wegovy (semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers beginning&nbsp;July 1, 2025.
WeightWatchers&nbsp;will <a target="_blank" href="https://www.prnewswire.com/news-releases/novo-nordisk-continues-efforts-to-support-patient-access-to-authentic-fda-approved-wegovy-and-prioritize-patient-safety-302492419.html" rel="noreferrer noopener">work</a> with&nbsp;CenterWell&nbsp;Pharmacy as the dispensing pharmacy managing prescription fulfillment and delivery for NovoCare Pharmacy.
Novo Nordisk said on Thursday that it is also introducing a new cash-offer price of&nbsp;$299, available through&nbsp;July 31, 2025.
This&nbsp;$299&nbsp;introductory price is available for self-paying patients new to the Wegovy&nbsp;savings offer or those who have not previously filled a prescription through NovoCare&nbsp;Pharmacy.
This builds on the previous&nbsp;$199&nbsp;Wegovy&nbsp;cash-offer patient price that expires on&nbsp;June 30, 2025.
Patients who redeemed the&nbsp;$199&nbsp;Wegovy&nbsp;savings offer&nbsp;between May 22 and June 30, 2025, will be eligible for the&nbsp;$299&nbsp;price on one fill&nbsp;between July 1 and July 31.
For subsequent months, self-paying patients will pay&nbsp;$499&nbsp;per month.
The company said in a press release that with all doses of FDA-approved Wegovy fully available nationwide, it is illegal under <a target="_blank" href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" rel="noreferrer noopener">U.S. compounding laws</a> to make or sell knockoff &#8220;semaglutide&#8221; drugs, with rare exceptions.&nbsp;
Price Action: NVO stock is up 1.77% at $68.90 during the premarket session at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46136734/rfk-jrs-cdc-panel-recommends-mercks-rsv-shot-for-infants" target="_blank" rel="noreferrer noopener">RFK Jr&#8217;s CDC Panel Recommends Merck&#8217;s RSV Shot For Infants</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk endorsed&nbsp;Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Satya Nadella&#8217;s&nbsp;perspective on&nbsp;the practical impact of AI, emphasizing its&nbsp;benefits to sectors like healthcare,&nbsp;education, and productivity.
What Happened: Musk, on X, supported Nadella&#8217;s views on AI&#8217;s progress, which were shared in a post by Nadella on June 25, 2025. Nadella, the CEO of&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), had stressed the importance of AI&#8217;s real-world outcomes over technical benchmarks at Y Combinator&#8217;s&nbsp;AI Startup School wherein Elon Musk commented &#8220;True&#8221;. Nadella stated that AI must produce results that are &#8220;socially useful.&#8221;
This shift in focus aligns with recent studies indicating AI&#8217;s&nbsp;potential to enhance GDP growth&nbsp;by addressing real-world challenges.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">True <a href="https://t.co/iFlmTUzLwx">https://t.co/iFlmTUzLwx</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1938086636941939098?ref_src=twsrc%5Etfw">June 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;If we really are not creating social surplus, economic surplus, as measured by countries and communities, we just can&#8217;t consumer energy.&#8221; stated Nadella. 
&#8220;The real question in the next five years is we&#8217;ve got to produce enough products that are creating great value,&#8221; he added.
He also pointed out&nbsp;that the true measure of&nbsp;AI&#8217;s progress lies in&nbsp;its ability to improve real-world&nbsp;outcomes rather than just achieving&nbsp;technical benchmarks. 
SEE ALSO: <a href="https://benzinga.com/crypto/25/06/46131453/bitcoin-ethereum-rangebound-dogecoin-dips-amid-potential-july-tariff-deadline-extension-analyst-predicts-btcs-next-big-move-once-it-breaks-out-of-this-range" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum Rangebound, Dogecoin Dips Amid Potential July Tariff Deadline Extension: Analyst Predicts BTC&#8217;s &#8216;Next Big Move&#8217; Once It Breaks Out Of This Range </a>
Why It Matters:&nbsp;Musk&#8217;s endorsement of Nadella&#8217;s view on AI&#8217;s real progress comes at a time when the tech industry is witnessing a shift towards focusing on&nbsp;the practical impact of AI.
CEO Satya Nadella believes that while AI is already <a href="https://www.benzinga.com/markets/tech/25/06/46111393/ai-is-already-speeding-up-discoveries-in-chemistry-and-physics-but-satya-nadella-says-the-real-breakthrough-will-come-when-we-add-quantum-computing-to-the-mix">driving major</a> scientific breakthroughs, its full transformative potential will be unlocked with the integration of quantum computing. Meanwhile, the growing role of AI in healthcare was highlighted, with Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) partnering with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) to speed up drug discovery and development. 
However, Wall Street remains divided on AI's future—while some investors are optimistic about its disruptive potential, others express concerns over associated risks and the lack of transparency in how it is being managed.
On a year-to-date basis, ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and Global X Artificial Intelligence &amp; Technology ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIQ#NASDAQ">AIQ</a>) climbed 24.85% and 13.05%, respectively. 
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/tech/25/06/46127671/amazon-loses-top-ai-leader-in-high-stakes-talent-shuffle">Amazon Loses Top AI Leader In High-Stakes Talent Shuffle </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

ARKK

MSFT

NVDA

TSLA

Elon Musk Backs Satya Nadella's View That AI Must Produce 'Socially Useful' Results: 'The Real Question In The Next Five Years Is...'

LFMD

Novo Nordisk Continues Wegovy Collaboration With LifeMD To Support Safe, Effective Obesity Treatment Access

&nbsp;
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy&reg; through NovoCare&reg; Pharmacy
&nbsp;
<ul>
<li>Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoing
	&nbsp;</li>
<li>A new $299 savings offer, available from July 1 &ndash; July 31, 2025, is designed to help new self-paying patients previously prescribed unapproved &quot;semaglutide&quot; start on FDA-approved Wegovy&reg;</li>
</ul>
PLAINSBORO, N.J., June 26, 2025 /PRNewswire/ -- Novo Nordisk continues expansion of patient access to Wegovy&reg;&nbsp;(semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers, a global leader in science-backed weight management, beginning July 1, 2025. WeightWatchers&nbsp;will work with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457989-1&amp;h=426787309&amp;u=https%3A%2F%2Fwww.centerwellpharmacy.com%2F&amp;a=CenterWell%C2%A0Pharmacy">CenterWell&nbsp;Pharmacy</a> as the dispensing pharmacy managing prescription fulfilment and delivery for NovoCare&reg;&nbsp;Pharmacy. By extending access to Wegovy&reg; through their integrated support system, WeightWatchers aims to provide patients with a more streamlined experience, along with convenient access to FDA-approved medication with the lifestyle support shown to improve outcomes.

Novo Nordisk Partners With WeightWatchers To Expand Wegovy Access Via NovoCare Pharmacy, Launches $299 Savings Offer For New Patients In July

Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">long-term treatment</a>.
While newer obesity-indicated GLP-1 therapies, such as semaglutide and tirzepatide, are increasingly used, poor persistence rates threaten the clinical and economic benefits of these medications.
Novo Nordisk A/S' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is the main input in Ozempic and Wegovy, and tirzepatide is a key ingredient in Eli Lilly &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly</a>
GLP-1 agonists have been linked to 10% to 20% weight loss in clinical trials, with some studies also showing reduced cardiovascular events in individuals without diabetes.
Yet, despite these benefits, long-term adherence remains a major hurdle. A 2023 real-world study by Prime Therapeutics found that just 27% of users remained adherent for one year, and only 15% persisted for two years. At three years, only 8.1% of users were still on treatment.
Even the best-performing drug, Wegovy, had a three-year persistence rate of just 14.3%.
The three-year analysis included 5,780 individuals continuously enrolled in a health plan after initiating GLP-1 treatment for obesity.
The group had a mean age of 46.7 years, and nearly 80% were women. Persistence rates varied widely by medication, from 14.3% with weekly semaglutide (Wegovy) to 2.5% with daily liraglutide (Victoza).
Over three years, only 12.5% of users met the standard for adherence based on medication possession, and more than one-third switched to a different GLP-1 therapy.
However, more recent <a target="_blank" href="https://www.primetherapeutics.com/w/prime-therapeutics-leading-research-shows-only-1-in-12-remain-on-a-glp-1-drug-for-obesity-at-three-years" rel="noreferrer noopener">data</a> suggests that persistence may be improving. In a separate year-over-year analysis involving 23,025 individuals initiating high-potency GLP-1s—Wegovy and Zepbound—one-year persistence rose from 33.2% in 2021 to 62.7% in 2024.
Tirzepatide (Zepbound), introduced in late 2023, had one-year persistence rates of over 62% in both 2023 and 2024.
This trend toward better short-term adherence is attributed to reduced supply shortages, improved dose escalation strategies, better side-effect management, and support programs.
Nonetheless, experts <a target="_blank" href="https://www.primetherapeutics.com/documents/d/primetherapeutics/prime-therapeutics_glp-1-therapy-to-treat-obesity-among-members-without-diabetes_three-year-persistence" rel="noreferrer noopener">caution</a> that poor long-term persistence among early adopters signals potential investment risk and limits the therapies' full clinical impact.
Further research is needed to understand why so many users discontinue treatment and whether newer approaches can sustain adherence over the long term.
Price Action: LLY stock is up 1.92% at $792.37, and NVO stock is down 5.03% at $67.17 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/46101643/did-the-fda-make-a-mistake-sareptas-elevidys-approval-under-scrutiny">Did The FDA Make A Mistake? Sarepta&#8217;s Elevidys Approval Under Scrutiny</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows

Telehealth darling Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) got slapped with a <a href="https://www.benzinga.com/quote/HIMS/news">34% stock crash</a> on Monday. Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) ended their relationship &#8211; and it wasn't amicable.
But is the plunge a chance to swipe right on the dip, or should investors ghost the stock altogether?
The high-growth telehealth firm, known for discreetly delivering everything from hair loss meds to mental health prescriptions, found itself at the wrong end of pharma giant Novo Nordisk's legal fury. At the center of the drama? Compounded versions of Wegovy, Novo's $8 billion blockbuster weight-loss drug.
What began as a workaround during supply shortages turned into a regulatory landmine. Now that the FDA says supply is back, compounded GLP-1 alternatives are no longer kosher &#8211; and Novo's accusing Hims of ignoring that. Hims says it's all about patient choice. Novo says it's illegal and dangerous.
Read Also: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45779301/hims-hers-zava-acquisition-deal-expands-its-market-opportunity-by-52-billion-analyst">Hims &amp; Hers ZAVA Acquisition Deal Expands Its Market Opportunity By $52 Billion: Analyst</a>
<h2 class="wp-block-heading">HIMS Stock's Been Hit, Valuations Are Lofty</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0624"><img loading="lazy" decoding="async" width="627" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24124229/Screenshot-2025-06-24-at-10.11.47-PM.png" alt="" class="wp-image-960187" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24124229/Screenshot-2025-06-24-at-10.11.47-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24124229/Screenshot-2025-06-24-at-10.11.47-PM-300x233.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0624" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Let's break it down:
<ul class="wp-block-list">
<li>Down 34.6% on Monday.</li>
<li>Down 66% year-to-date.</li>
<li>Trading below its eight, 20 and 50-day moving averages.</li>
<li>RSI (relative strength index) at 38.69 &#8211; nearing oversold, but not quite screaming reversal yet.</li>
</ul>
To make matters worse, HIMS is trading at a lofty forward P/E of 69.4, over <a href="https://seekingalpha.com/symbol/HIMS/valuation/metrics">2.5x</a> the sector median. Its PEG ratio of 3.9 suggests that even with high growth, the valuation's hard to justify unless earnings explode.
<h2 class="wp-block-heading">GLP-1 Was The Rocket Fuel… Until It Wasn't</h2>
Hims generated roughly $200–225 million in 2024 from its GLP-1 business — a massive chunk of its $1.48 billion in revenue. But Novo Nordisk just nuked that rocket mid-flight. Analysts are now re-evaluating Hims' forward growth without GLP-1 steroids in the mix.
And with Novo signaling FDA escalation, this isn't just a one-off spat. It's a broader industry warning shot. The Telehealth wild west is running into the FDA's regulatory sheriff.
<h2 class="wp-block-heading">But Wait — Is There A Long-Term Case Here?</h2>
Not everything is burning. Over 80% of Hims' revenue still comes from non-weight-loss verticals. Acne, anxiety, ED — these markets aren't going anywhere, and Hims remains one of the most recognizable DTC health brands for millennials and Gen Z.
From a technical lens:
<ul class="wp-block-list">
<li>MACD (moving average convergence/divergence) indicator is positive at 0.48 — a bullish signal.</li>
<li>Still above the 200-day moving average ($33.61), indicating long-term trend support hasn't fully broken.</li>
</ul>
<h2 class="wp-block-heading">Buy-the-Dip Or Just A Trip?</h2>
Hims stock is caught in a regulatory firestorm, and its valuation doesn't offer much margin for error. But the business isn&#8217;t going away, and with the GLP-1 bubble deflating across smaller players, Hims may get a chance to re-anchor its narrative.
If you're a long-term bull who believes in the platform beyond weight-loss fads — this could be your messy, high-risk entry point.
But if you're chasing quick rebounds, beware: the market may want to see actual legal clarity before it forgives and forgets.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46067629/hims-ceo-slams-novo-nordisk-for-anticompetitive-demands-after-ozempic-maker-abruptly-ends-partnership-we-refuse-to-be-strong-armed">Hims CEO Slams Novo Nordisk For &#8216;Anticompetitive Demands&#8217; After Ozempic Maker Abruptly Ends Partnership: &#8216;We Refuse To Be Strong-Armed&#8217;</a></li>
</ul>

Technicals

Tech

Trading Ideas

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?

<a href="https://nypost.com/2025/06/24/health/weight-loss-drugs-like-ozempic-may-prevent-dementia-study/" title="https://nypost.com/2025/06/24/health/weight-loss-drugs-like-ozempic-may-prevent-dementia-study/">https://nypost.com/2025/06/24/health/weight-loss-drugs-like-ozempic-may-prevent-dementia-study/</a>

"Weight loss drugs like Ozempic may prevent dementia: study" - NY Post

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has reportedly <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">launched its weight-loss</a> drug Wegovy (semaglutide) in India to compete with Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
In March this year, U.S. pharma giant Eli Lilly launched its popular weight loss drug Mounjaro (tirzepatide) in India. It is expected to have the second-largest population of overweight or <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">obese people by 2050</a>.
A Reuters report on Tuesday said that Wegovy, a weekly injection, will be available in pharmacies by the end of this month. It could take some market share away from Eli Lilly. Meanwhile, sales of Eli Lilly's drug Mounjaro rose 60% between April and May, the report highlighted, citing industry analysts.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" rel="noreferrer noopener">Novo Nordisk&#8217;s Weight Loss Injection CagriSema Data Sparks Investor Concern</a>
Novo Nordisk told Reuters that Wegovy is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. The first three will be priced at 4,336 rupees ($50.7), and the monthly cost will be 17,345 rupees ($201.4), similar to Eli Lilly&#8217;s Mounjaro.
The Reuters report added that Wegovy&#8217;s 1.7 mg dose will be priced at 24,280 rupees ($281.90) and 2.4 mg at 26,015 rupees.
Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 Indian rupees ($50.86) for a 5 mg vial and 3,500 rupees for a 2.5 mg vial, its lowest dose, the company told Reuters. Its highest dose is 15 mg.
On Monday, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for updating the Ozempic (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.
Following the <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916358" rel="noreferrer noopener">positive</a> opinion from the CHMP, Novo Nordisk expects the European Commission to implement the label update within approximately two months.
Novo Nordisk has also filed for a label expansion of Ozempic in the U.S., and a decision is expected in the last quarter of 2025.
Based on data from the SOUL trial, Novo Nordisk has also filed with the EMA and FDA for a label expansion for Rybelsus.
This could potentially make Rybelsus the first and only oral GLP-1 RA with proven cardiovascular (CV) benefits. A decision is also expected in the second half of 2025.
On Monday, the New England Journal of Medicine (NEJM) published results from Novo Nordisk&#8217;s phase 3 REDEFINE 1 trial of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/46050655/novo-nordisks-weight-loss-injection-cagrisema-data-sparks-investors-concern" rel="noreferrer noopener">complication and without diabetes</a>.
Price Action: NVO stock is up 1.25% at $70.59 at last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46067629/hims-ceo-slams-novo-nordisk-for-anticompetitive-demands-after-ozempic-maker-abruptly-ends-partnership-we-refuse-to-be-strong-armed" target="_blank" rel="noreferrer noopener">Hims CEO Slams Novo Nordisk For &#8216;Anticompetitive Demands&#8217; After Ozempic Maker Abruptly Ends Partnership: &#8216;We Refuse To Be Strong-Armed&#8217;</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly

<a href="https://ml-eu.globenewswire.com/Resource/Download/4c1df447-fb7d-4946-9d1a-9338efde42d3">https://ml-eu.globenewswire.com/Resource/Download/4c1df447-fb7d-4946-9d1a-9338efde42d3</a>

'Ozempic Receives EU Recommendation In Peripheral Arterial Disease, Cementing The Broad Benefits Of Semaglutide For People With Type 2 Diabetes And Comorbidities '

Wall Street showed unexpected resilience Monday as investors looked past a sharp escalation in the Middle East, where Iran fired missiles at U.S. military bases in Qatar and Iraq — just 48 hours after American strikes <a href="https://www.benzinga.com/topic/iran">targeted Iranian nuclear facilities.</a>
According to Axios, citing Israeli officials, Iran launched six ballistic missiles at Al Udeid Air Base in Qatar, the largest U.S. military presence in the Middle East. Another missile was reportedly fired at a U.S. base in Iraq. 
Despite the rising geopolitical risks, U.S. equity markets held firm. By midday trading in New York, the Nasdaq 100 rose 0.7% to 21,755, the S&amp;P 500 added 0.4% to 5,990, while the Dow Jones Industrial Average inched 0.3% higher to 42,321. Small caps underperformed, with the Russell 2000 down 0.1% to 2,107.
President Donald Trump is scheduled to meet with his national security team at 1 p.m. ET at the White House to assess the evolving threat landscape.
Monday's session defied expectations in energy markets. West Texas Intermediate crude fell over 5% to below $70 a barrel, on track for its worst one-day drop since early April and its lowest level in a week.
Gold rose 0.6% to $3,387 per ounce. The day&#8217;s standout gainer was the U.S. bond market, with yields falling across major maturities. 
The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) gained nearly 1%, surging to levels last seen in May 8. 
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day chg. %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,755.49</td>
<td>0.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,988.77</td>
<td>0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,321.51</td>
<td>0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,107.04</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 1:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.5% to $550.39.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.4% up to $423.40.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.5% to $529.89.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) held steady at $209.28.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 1.5%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 2.6%.</li>
</ul>
<h1 class="wp-block-heading">Monday&#8217;s Stock Movers</h1>
<ul class="wp-block-list">
<li>FactSet Research Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) gained 3.4% despite missing earnings expectations, buoyed by stronger-than-expected forward guidance.</li>
<li>Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) said Monday it has terminated its partnership with Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) for selling weight-loss drugs, including Wegovy. Shares of Novo fell 6%, while Hims &amp; Hers plunged 33%.</li>
<li>
<path d="M12.668 10.667C12.668 9.95614 12.668 9.46258 12.6367 9.0791C12.6137 8.79732 12.5758 8.60761 12.5244 8.46387L12.4688 8.33399C12.3148 8.03193 12.0803 7.77885 11.793 7.60254L11.666 7.53125C11.508 7.45087 11.2963 7.39395 10.9209 7.36328C10.5374 7.33197 10.0439 7.33203 9.33301 7.33203H6.5C5.78896 7.33203 5.29563 7.33195 4.91211 7.36328C4.63016 7.38632 4.44065 7.42413 4.29688 7.47559L4.16699 7.53125C3.86488 7.68518 3.61186 7.9196 3.43555 8.20703L3.36524 8.33399C3.28478 8.49198 3.22795 8.70352 3.19727 9.0791C3.16595 9.46259 3.16504 9.95611 3.16504 10.667V13.5C3.16504 14.211 3.16593 14.7044 3.19727 15.0879C3.22797 15.4636 3.28473 15.675 3.36524 15.833L3.43555 15.959C3.61186 16.2466 3.86474 16.4807 4.16699 16.6348L4.29688 16.6914C4.44063 16.7428 4.63025 16.7797 4.91211 16.8027C5.29563 16.8341 5.78896 16.835 6.5 16.835H9.33301C10.0439 16.835 10.5374 16.8341 10.9209 16.8027C11.2965 16.772 11.508 16.7152 11.666 16.6348L11.793 16.5645C12.0804 16.3881 12.3148 16.1351 12.4688 15.833L12.5244 15.7031C12.5759 15.5594 12.6137 15.3698 12.6367 15.0879C12.6681 14.7044 12.668 14.211 12.668 13.5V10.667ZM13.998 12.665C14.4528 12.6634 14.8011 12.6602 15.0879 12.6367C15.4635 12.606 15.675 12.5492 15.833 12.4688L15.959 12.3975C16.2466 12.2211 16.4808 11.9682 16.6348 11.666L16.6914 11.5361C16.7428 11.3924 16.7797 11.2026 16.8027 10.9209C16.8341 10.5374 16.835 10.0439 16.835 9.33301V6.5C16.835 5.78896 16.8341 5.29563 16.8027 4.91211C16.7797 4.63025 16.7428 4.44063 16.6914 4.29688L16.6348 4.16699C16.4807 3.86474 16.2466 3.61186 15.959 3.43555L15.833 3.36524C15.675 3.28473 15.4636 3.22797 15.0879 3.19727C14.7044 3.16593 14.211 3.16504 13.5 3.16504H10.667C9.9561 3.16504 9.46259 3.16595 9.0791 3.19727C8.79739 3.22028 8.6076 3.2572 8.46387 3.30859L8.33399 3.36524C8.03176 3.51923 7.77886 3.75343 7.60254 4.04102L7.53125 4.16699C7.4508 4.32498 7.39397 4.53655 7.36328 4.91211C7.33985 5.19893 7.33562 5.54719 7.33399 6.00195H9.33301C10.022 6.00195 10.5791 6.00131 11.0293 6.03809C11.4873 6.07551 11.8937 6.15471 12.2705 6.34668L12.4883 6.46875C12.984 6.7728 13.3878 7.20854 13.6533 7.72949L13.7197 7.87207C13.8642 8.20859 13.9292 8.56974 13.9619 8.9707C13.9987 9.42092 13.998 9.97799 13.998 10.667V12.665ZM18.165 9.33301C18.165 10.022 18.1657 10.5791 18.1289 11.0293C18.0961 11.4302 18.0311 11.7914 17.8867 12.1279L17.8203 12.2705C17.5549 12.7914 17.1509 13.2272 16.6553 13.5313L16.4365 13.6533C16.0599 13.8452 15.6541 13.9245 15.1963 13.9619C14.8593 13.9895 14.4624 13.9935 13.9951 13.9951C13.9935 14.4624 13.9895 14.8593 13.9619 15.1963C13.9292 15.597 13.864 15.9576 13.7197 16.2939L13.6533 16.4365C13.3878 16.9576 12.9841 17.3941 12.4883 17.6982L12.2705 17.8203C11.8937 18.0123 11.4873 18.0915 11.0293 18.1289C10.5791 18.1657 10.022 18.165 9.33301 18.165H6.5C5.81091 18.165 5.25395 18.1657 4.80371 18.1289C4.40306 18.0962 4.04235 18.031 3.70606 17.8867L3.56348 17.8203C3.04244 17.5548 2.60585 17.151 2.30176 16.6553L2.17969 16.4365C1.98788 16.0599 1.90851 15.6541 1.87109 15.1963C1.83431 14.746 1.83496 14.1891 1.83496 13.5V10.667C1.83496 9.978 1.83432 9.42091 1.87109 8.9707C1.90851 8.5127 1.98772 8.10625 2.17969 7.72949L2.30176 7.51172C2.60586 7.0159 3.04236 6.6122 3.56348 6.34668L3.70606 6.28027C4.04237 6.136 4.40303 6.07083 4.80371 6.03809C5.14051 6.01057 5.53708 6.00551 6.00391 6.00391C6.00551 5.53708 6.01057 5.14051 6.03809 4.80371C6.0755 4.34588 6.15483 3.94012 6.34668 3.56348L6.46875 3.34473C6.77282 2.84912 7.20856 2.44514 7.72949 2.17969L7.87207 2.11328C8.20855 1.96886 8.56979 1.90385 8.9707 1.87109C9.42091 1.83432 9.978 1.83496 10.667 1.83496H13.5C14.1891 1.83496 14.746 1.83431 15.1963 1.87109C15.6541 1.90851 16.0599 1.98788 16.4365 2.17969L16.6553 2.30176C17.151 2.60585 17.5548 3.04244 17.8203 3.56348L17.8867 3.70606C18.031 4.04235 18.0962 4.40306 18.1289 4.80371C18.1657 5.25395 18.165 5.81091 18.165 6.5V9.33301Z"></path>
<path d="M10.9153 1.83987L11.2942 1.88772L11.4749 1.91507C13.2633 2.24201 14.4107 4.01717 13.9749 5.78225L13.9261 5.95901L13.3987 7.6719C13.7708 7.67575 14.0961 7.68389 14.3792 7.70608C14.8737 7.74486 15.3109 7.82759 15.7015 8.03323L15.8528 8.11819C16.5966 8.56353 17.1278 9.29625 17.3167 10.1475L17.347 10.3096C17.403 10.69 17.3647 11.0832 17.2835 11.5098C17.2375 11.7517 17.1735 12.0212 17.096 12.3233L16.8255 13.3321L16.4456 14.7276C16.2076 15.6001 16.0438 16.2356 15.7366 16.7305L15.595 16.9346C15.2989 17.318 14.9197 17.628 14.4866 17.8408L14.2982 17.9258C13.6885 18.1774 12.9785 18.1651 11.9446 18.1651H7.33331C6.64422 18.1651 6.08726 18.1657 5.63702 18.1289C5.23638 18.0962 4.87565 18.031 4.53936 17.8867L4.39679 17.8203C3.87576 17.5549 3.43916 17.151 3.13507 16.6553L3.013 16.4366C2.82119 16.0599 2.74182 15.6541 2.7044 15.1963C2.66762 14.7461 2.66827 14.1891 2.66827 13.5V11.667C2.66827 10.9349 2.66214 10.4375 2.77569 10.0137L2.83722 9.81253C3.17599 8.81768 3.99001 8.05084 5.01397 7.77639L5.17706 7.73928C5.56592 7.66435 6.02595 7.66799 6.66632 7.66799C6.9429 7.66799 7.19894 7.52038 7.33624 7.2803L10.2562 2.16995L10.3118 2.08792C10.4544 1.90739 10.6824 1.81092 10.9153 1.83987ZM7.33136 14.167C7.33136 14.9841 7.33714 15.2627 7.39386 15.4746L7.42999 15.5918C7.62644 16.1686 8.09802 16.6134 8.69171 16.7725L8.87042 16.8067C9.07652 16.8323 9.38687 16.835 10.0003 16.835H11.9446C13.099 16.835 13.4838 16.8228 13.7903 16.6963L13.8997 16.6465C14.1508 16.5231 14.3716 16.3444 14.5433 16.1221L14.6155 16.0166C14.7769 15.7552 14.8968 15.3517 15.1624 14.378L15.5433 12.9824L15.8079 11.9922C15.8804 11.7102 15.9368 11.4711 15.9769 11.2608C16.0364 10.948 16.0517 10.7375 16.0394 10.5791L16.0179 10.4356C15.9156 9.97497 15.641 9.57381 15.2542 9.31253L15.0814 9.20999C14.9253 9.12785 14.6982 9.06544 14.2747 9.03225C13.8477 8.99881 13.2923 8.99807 12.5003 8.99807C12.2893 8.99807 12.0905 8.89822 11.9651 8.72854C11.8398 8.55879 11.8025 8.33942 11.8646 8.13772L12.6556 5.56741L12.7054 5.36331C12.8941 4.35953 12.216 3.37956 11.1878 3.2178L8.49054 7.93948C8.23033 8.39484 7.81431 8.72848 7.33136 8.88967V14.167ZM3.99835 13.5C3.99835 14.2111 3.99924 14.7044 4.03058 15.0879C4.06128 15.4636 4.11804 15.675 4.19854 15.833L4.26886 15.959C4.44517 16.2466 4.69805 16.4808 5.0003 16.6348L5.13019 16.6905C5.27397 16.7419 5.46337 16.7797 5.74542 16.8028C5.97772 16.8217 6.25037 16.828 6.58722 16.8311C6.41249 16.585 6.27075 16.3136 6.1712 16.0215L6.10968 15.8194C5.99614 15.3956 6.00128 14.899 6.00128 14.167V9.00296C5.79386 9.0067 5.65011 9.01339 5.53741 9.02737L5.3587 9.06057C4.76502 9.21965 4.29247 9.66448 4.09601 10.2412L4.06085 10.3584C4.00404 10.5705 3.99835 10.8493 3.99835 11.667V13.5Z"></path>
<path d="M12.6687 5.83304C12.6687 5.22006 12.6649 4.91019 12.6394 4.70413L12.6062 4.52542C12.4471 3.93179 12.0022 3.45922 11.4255 3.26272L11.3083 3.22757C11.0963 3.17075 10.8175 3.16507 9.99974 3.16507H8.0554C7.04558 3.16507 6.62456 3.17475 6.32982 3.26175L6.2097 3.30374C5.95005 3.41089 5.71908 3.57635 5.53392 3.78616L5.45677 3.87796C5.30475 4.0748 5.20336 4.33135 5.03392 4.91702L4.83763 5.6221L4.45677 7.01761C4.24829 7.78204 4.10326 8.31846 4.02318 8.73929C3.94374 9.15672 3.94298 9.39229 3.98119 9.56448L4.03587 9.75784C4.18618 10.1996 4.50043 10.5702 4.91771 10.7901L5.05052 10.8477C5.20009 10.9014 5.40751 10.9429 5.72533 10.9678C6.15231 11.0012 6.70771 11.002 7.49974 11.002C7.71076 11.002 7.90952 11.1018 8.0349 11.2715C8.14465 11.4201 8.18683 11.6067 8.15404 11.7862L8.13548 11.8623L7.34447 14.4326C7.01523 15.5033 7.71404 16.6081 8.81126 16.7813L11.5095 12.0606L11.5827 11.9405C11.8445 11.5461 12.2289 11.2561 12.6687 11.1094V5.83304ZM17.3318 8.33304C17.3318 8.97366 17.3364 9.43432 17.2615 9.82327L17.2234 9.98538C16.949 11.0094 16.1821 11.8233 15.1872 12.1621L14.9861 12.2237C14.5624 12.3372 14.0656 12.3321 13.3337 12.3321C13.0915 12.3321 12.8651 12.4453 12.7204 12.6348L12.6638 12.7198L9.74388 17.8301C9.61066 18.0631 9.35005 18.1935 9.08372 18.1602L8.70579 18.1123C6.75379 17.8682 5.49542 15.9213 6.07396 14.041L6.60033 12.3272C6.22861 12.3233 5.90377 12.3161 5.62083 12.294C5.18804 12.26 4.79914 12.1931 4.44701 12.0391L4.29857 11.9668C3.52688 11.5605 2.95919 10.8555 2.72533 10.0205L2.68333 9.85257C2.58769 9.42154 2.62379 8.97768 2.71654 8.49026C2.80865 8.00634 2.97082 7.41139 3.17357 6.668L3.55443 5.27249L3.74583 4.58011C3.9286 3.94171 4.10186 3.45682 4.40404 3.06546L4.53685 2.9053C4.85609 2.54372 5.25433 2.25896 5.70189 2.07425L5.93626 1.99222C6.49455 1.82612 7.15095 1.83499 8.0554 1.83499H12.6667C13.3558 1.83499 13.9128 1.83434 14.363 1.87112C14.8208 1.90854 15.2266 1.98789 15.6033 2.17972L15.821 2.30179C16.317 2.6059 16.7215 3.04226 16.987 3.56351L17.0535 3.70608C17.1977 4.04236 17.2629 4.40311 17.2956 4.80374C17.3324 5.25398 17.3318 5.81094 17.3318 6.50003V8.33304ZM13.9978 10.9961C14.3321 10.9901 14.5013 10.977 14.6413 10.9395L14.7585 10.9033C15.3353 10.7069 15.7801 10.2353 15.9392 9.64163L15.9724 9.46292C15.998 9.25682 16.0017 8.94657 16.0017 8.33304V6.50003C16.0017 5.78899 16.0008 5.29566 15.9695 4.91214C15.9464 4.6301 15.9086 4.44069 15.8572 4.2969L15.8015 4.16702C15.6475 3.86478 15.4133 3.6119 15.1257 3.43558L14.9997 3.36526C14.8418 3.28477 14.6302 3.228 14.2546 3.19729C14.0221 3.1783 13.7491 3.17109 13.4118 3.168C13.6267 3.47028 13.7914 3.81126 13.8904 4.18069L13.9275 4.34378C13.981 4.62163 13.9947 4.93582 13.9978 5.3262V10.9961Z"></path>
<path d="M9.75122 4.09203C9.75122 3.61482 9.21964 3.35044 8.84399 3.60277L8.77173 3.66039L6.55396 5.69262C6.05931 6.14604 5.43173 6.42255 4.7688 6.48461L4.48267 6.49828C3.52474 6.49851 2.74829 7.27565 2.74829 8.23363V11.7668C2.74829 12.7248 3.52474 13.501 4.48267 13.5012C5.24935 13.5012 5.98874 13.7889 6.55396 14.3069L8.77173 16.3401L8.84399 16.3967C9.21966 16.6493 9.75122 16.3858 9.75122 15.9084V4.09203ZM17.2483 10.0002C17.2483 8.67623 16.9128 7.43233 16.3235 6.34691L17.4924 5.71215C18.1849 6.9875 18.5784 8.4491 18.5784 10.0002C18.5783 11.5143 18.2033 12.9429 17.5413 14.1965C17.3697 14.5212 16.9675 14.6453 16.6428 14.4739C16.3182 14.3023 16.194 13.9001 16.3655 13.5754C16.9288 12.5086 17.2483 11.2927 17.2483 10.0002ZM13.9182 10.0002C13.9182 9.1174 13.6268 8.30445 13.135 7.64965L14.1985 6.85082C14.8574 7.72804 15.2483 8.81952 15.2483 10.0002L15.2336 10.3938C15.166 11.3044 14.8657 12.1515 14.3918 12.8743L14.3069 12.9797C14.0889 13.199 13.7396 13.2418 13.4709 13.0657C13.164 12.8643 13.0784 12.4528 13.2795 12.1457L13.4231 11.9084C13.6935 11.4246 13.8643 10.8776 13.9075 10.2942L13.9182 10.0002ZM13.2678 6.71801C13.5615 6.49772 13.978 6.55727 14.1985 6.85082L13.135 7.64965C12.9144 7.35599 12.9742 6.93858 13.2678 6.71801ZM16.5911 5.44555C16.9138 5.27033 17.3171 5.38949 17.4924 5.71215L16.3235 6.34691C16.1483 6.02419 16.2684 5.62081 16.5911 5.44555ZM11.0813 15.9084C11.0813 17.5226 9.22237 18.3912 7.9895 17.4202L7.87231 17.3205L5.65552 15.2873C5.33557 14.9941 4.91667 14.8313 4.48267 14.8313C2.7902 14.8311 1.41821 13.4594 1.41821 11.7668V8.23363C1.41821 6.54111 2.7902 5.16843 4.48267 5.1682L4.64478 5.16039C5.02003 5.12526 5.37552 4.96881 5.65552 4.71215L7.87231 2.67992L7.9895 2.58031C9.22237 1.60902 11.0813 2.47773 11.0813 4.09203V15.9084Z"></path>
<path d="M12.0303 4.11328C13.4406 2.70317 15.7275 2.70305 17.1377 4.11328C18.5474 5.52355 18.5476 7.81057 17.1377 9.2207L10.8457 15.5117C10.522 15.8354 10.2868 16.0723 10.0547 16.2627L9.82031 16.4395C9.61539 16.5794 9.39783 16.7003 9.1709 16.7998L8.94141 16.8916C8.75976 16.9582 8.57206 17.0072 8.35547 17.0518L7.59082 17.1865L5.19727 17.5859C5.05455 17.6097 4.90286 17.6358 4.77441 17.6455C4.67576 17.653 4.54196 17.6555 4.39648 17.6201L4.24707 17.5703C4.02415 17.4746 3.84119 17.3068 3.72559 17.0957L3.67969 17.0029C3.59322 16.8013 3.59553 16.6073 3.60547 16.4756C3.61519 16.3473 3.6403 16.1963 3.66406 16.0537L4.06348 13.6602C4.1638 13.0582 4.22517 12.6732 4.3584 12.3096L4.45117 12.0791C4.55073 11.8521 4.67152 11.6346 4.81152 11.4297L4.9873 11.1953C5.17772 10.9632 5.4146 10.728 5.73828 10.4043L12.0303 4.11328ZM6.67871 11.3447C6.32926 11.6942 6.14542 11.8803 6.01953 12.0332L5.90918 12.1797C5.81574 12.3165 5.73539 12.4618 5.66895 12.6133L5.60742 12.7666C5.52668 12.9869 5.48332 13.229 5.375 13.8789L4.97656 16.2725L4.97559 16.2744H4.97852L7.37207 15.875L8.08887 15.749C8.25765 15.7147 8.37336 15.6839 8.4834 15.6436L8.63672 15.5811C8.78817 15.5146 8.93356 15.4342 9.07031 15.3408L9.2168 15.2305C9.36965 15.1046 9.55583 14.9207 9.90527 14.5713L14.8926 9.58301L11.666 6.35742L6.67871 11.3447ZM16.1963 5.05371C15.3054 4.16304 13.8616 4.16305 12.9707 5.05371L12.6074 5.41602L15.833 8.64258L16.1963 8.2793C17.0869 7.38845 17.0869 5.94456 16.1963 5.05371Z"></path>
<path d="M4.58301 1.7832C4.72589 1.7832 4.84877 1.88437 4.87695 2.02441C4.99384 2.60873 5.22432 3.11642 5.58398 3.50391C5.94115 3.88854 6.44253 4.172 7.13281 4.28711C7.27713 4.3114 7.38267 4.43665 7.38281 4.58301C7.38281 4.7295 7.27723 4.8546 7.13281 4.87891C6.44249 4.99401 5.94116 5.27746 5.58398 5.66211C5.26908 6.00126 5.05404 6.43267 4.92676 6.92676L4.87695 7.1416C4.84891 7.28183 4.72601 7.38281 4.58301 7.38281C4.44013 7.38267 4.31709 7.28173 4.28906 7.1416C4.17212 6.55728 3.94179 6.04956 3.58203 5.66211C3.22483 5.27757 2.72347 4.99395 2.0332 4.87891C1.88897 4.85446 1.7832 4.72938 1.7832 4.58301C1.78335 4.43673 1.88902 4.3115 2.0332 4.28711C2.72366 4.17203 3.22481 3.88861 3.58203 3.50391C3.94186 3.11638 4.17214 2.60888 4.28906 2.02441L4.30371 1.97363C4.34801 1.86052 4.45804 1.78333 4.58301 1.7832Z"></path>
<div class="text-center"></div>
<path d="M6.24992 11.0417C6.65578 11.0417 7.04227 10.9587 7.39339 10.809C7.05099 11.7065 6.35374 12.9827 5.29864 13.1333C4.84303 13.1985 4.52644 13.6206 4.59153 14.0762C4.65662 14.5318 5.07873 14.8484 5.53434 14.7832C7.66169 14.4794 8.93792 12.0592 9.30742 10.1591C9.50975 9.11833 9.48792 7.98412 9.04084 7.03938C8.53525 5.97097 7.43538 5.20335 6.23748 5.20834C4.63238 5.21504 3.33325 6.5183 3.33325 8.12498C3.33325 9.73583 4.63909 11.0417 6.24992 11.0417Z"></path>
<path d="M13.4832 11.0417C13.889 11.0417 14.2755 10.9587 14.6267 10.809C14.2843 11.7065 13.587 12.9827 12.5319 13.1333C12.0763 13.1985 11.7597 13.6206 11.8248 14.0762C11.8899 14.5318 12.312 14.8484 12.7676 14.7832C14.8949 14.4794 16.1712 12.0592 16.5407 10.1591C16.743 9.11833 16.7212 7.98412 16.2741 7.03938C15.7685 5.97097 14.6687 5.20335 13.4708 5.20834C11.8656 5.21504 10.5665 6.5183 10.5665 8.12498C10.5665 9.73583 11.8724 11.0417 13.4832 11.0417Z"></path>
<div aria-hidden="true" data-edge="true" class="pointer-events-none h-px w-px"></div>
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) surged nearly 10% after CEO Elon Musk touted the "successful" weekend rollout of the company's robotaxi fleet in Austin, Texas. Read Now:</li>
<li><a href="https://www.benzinga.com/news/25/06/46055156/sp500-oil-crisis-performance-iran">War, Oil, And S&amp;P 500: Here&#8217;s How The Stock Market Behaves In Energy Crises</a> Photo: Thapana Studio via Shutterstock </li>
</ul>

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Treasuries

Global

Econ #s

Economics

ETFs

SPDR Dow Jones Industrial Average ETF Trust

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

Stocks Rise, Oil Tumbles Despite Iran's Strikes On US Bases: What's Driving Markets Monday?

<ul>
<li>HIMS</li>
<li>TSLA</li>
<li>CRCL</li>
<li>GLD</li>
<li>GOOGL</li>
<li>BULL</li>
<li>GOOG</li>
<li>NVO</li>
<li>AMD</li>
<li>UNH</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BULL

CRCL

GOOG

GOOGL

Top 10 Trending Stocks On WallStreetBets As Of June 23, 2025 (Via Swaggy Stocks)

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares are trading lower Monday after Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) terminated its collaboration <a href="https://www.benzinga.com/pressreleases/25/06/n46049309/novo-nordisk-terminates-collaboration-with-hims-hers-health-inc-due-to-concerns-about-their-illega">with the company</a>. 
What Happened: Novo Nordisk announced Monday that it will no longer be working with Hims &amp; Hers Health. As a result, the company will no longer have direct access to Wegovy through the NovoCare Pharmacy. 
Novo Nordisk alleged in a press release that Hims &amp; Hers Health has failed to follow laws that prohibit mass sales of compounded drugs under the false appearance of &#8220;personalization&#8221; and has used deceptive marketing with disregard for patient safety.
&#8220;Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy,&#8221; said&nbsp;Dave Moore, executive vice president of Novo Nordisk&#8217;s U.S. operations.
&#8220;We will work with telehealth companies to provide direct access to Wegovy&nbsp;that share our commitment to patient safety – and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action.&#8221;
The news comes after the U.S. Food and Drug Administration's (FDA)&nbsp;said in April that Semaglutide, the active ingredient in popular weight-loss drugs like Wegovy, could&nbsp;<a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize" target="_blank" rel="noreferrer noopener">no longer be offered</a>&nbsp;in compounded drugs by outsourcing facilities.
Shares of Hims &amp; Hers Health fell as the FDA action took effect. Hims &amp; Hers sells cheaper versions of popular weight-loss drugs, known as compounded drugs. Regulators allow compounded versions of drugs to enter the market to meet demand when there is a shortage. The company generated over $225 million in revenue in 2024 from its GLP-1 product.
Novo Nordisk on Monday said it&#8217;s &#8220;deeply concerned&#8221; and will continue to take proactive measures to keep U.S. patients safe from &#8220;knock-off drugs made with foreign illicit active pharmaceutical ingredients.&#8221;
HIMS Price Action:&nbsp;<a href="http://benzinga.com/quote/hims" target="_blank" rel="noreferrer noopener">Hims &amp; Hers Health shares</a>&nbsp;were down 23.9% at $48.90 at the time of publication Monday, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46048974/eli-lillys-investigational-oral-pill-shows-weight-loss-benefits-with-lingering-side-effect-concerns">Eli Lilly&#8217;s Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46048611/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-7">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo: Lori Butcher/Shutterstock.

Movers

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

On Sunday, The New England Journal of Medicine (NEJM) published results from Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">phase 3 REDEFINE 1 trial</a> of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">weight-related medical</a> complication and without diabetes.
CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).
CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analog, cagrilintide. 
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/06/45927887/novo-nordisk-moves-amycretin-into-phase-3-trials-for-weight-management-becomes-europes-largest-company" target="_blank" rel="noreferrer noopener">Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe&#8217;s Largest Company</a>
<h2 class="wp-block-heading">REDEFINE 1 Trial</h2>
If all patients adhered to treatment, CagriSema <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916353" rel="noreferrer noopener">resulted</a> in a greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group.
When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved a statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group.
In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI &lt; 30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment.
In the placebo group,10.2% reached that threshold at 68 weeks.
Select confirmatory secondary endpoints showed that if all participants adhered to treatment, 40.4% of those receiving CagriSema achieved a weight reduction of ≥25%.
Additionally, 23.1% lost ≥30% of their body weight.
When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction, and 19.3% achieved ≥30%.
In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus –5.7% and –4.3% for the placebo group, respectively.
These data, along with the related <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44244966/novo-nordisks-combo-drug-cagrisema-shows-16-weight-reduction-in-second-phase-3-trial-stock-falls" rel="noreferrer noopener">phase 3 REDEFINE 2 study</a> conducted in adults with overweight or obesity and type 2 diabetes, were presented at the American Diabetes Association.
<h2 class="wp-block-heading">REDEFINE 2 Study</h2>
If all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was –15.7% with CagriSema versus –3.1% with placebo.
When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was –13.7% with CagriSema versus –3.4% with placebo.
A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by &gt;5% (83.6% vs. 30.8% of participants), ≥10% (65.6% vs. 10.3%), ≥15% (43.9% vs. 2.4%), and ≥20% (22.9% vs. 0.5%;)
The safety results from CagriSema in REDEFINE 2 were similar to those reported in the REDEFINE 1 trial.
Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2.
<h2 class="wp-block-heading">Market Reaction</h2>
NVO experienced a decline of over 7% in premarket trading on Monday; the market&#8217;s reaction suggests that Novo Nordisk&#8217;s CagriSema has been perceived to have a less favorable side effect profile when compared to Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) orforglipron.
In Eli Lilly&#8217;s ACHIEVE-1 trial, the most common adverse events for participants treated with orforglipron (3 mg, 12 mg and 36 mg, respectively) were diarrhea (19%, 21% and 26%) vs. 9% with placebo, nausea (13%, 18% and 16%) vs. 2% with placebo, dyspepsia (11%, 20% and 15%) vs. 7% with placebo, constipation (8%, 17% and 14%) vs. 4% with placebo, and vomiting (5%, 7% and 14%) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46041936/lillys-oral-glp-1-orforglipron-showed-compelling-efficacy-and-a-safety-profile-consistent-with-inj" rel="noreferrer noopener">vs. 1% with placebo</a>.
In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs. 39.9% with placebo), including nausea (55% vs. 12.6 %), constipation (30.7% vs. 11.6%), vomiting (26.1% vs. 4.1%) and mainly were transient and mild-to-moderate in severity.
Adding to the investor concerns, William Blair analysts expressed disappointment, stating, &#8220;We had hoped that the amylin component could provide a higher magnitude of weight loss among patients living with type 2 diabetes. Unfortunately, the hypothesis did not come to fruition, and in our view, there is no evidence to suggest CagriSema should be prescribed over Zepbound in any subpopulation, based on the available data released to date.&#8221;
Analyst Andy Hsieh further elaborated that the &#8220;high frequency of adverse events could fuel uncertainty over the asset&#8217;s differentiation against approved (Zepbound) or late-stage investigational (retatrutide and MariTide) compounds.&#8221;
Price Action: At the last check on Monday, NVO stock was down 7.10% to $68.53 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46048974/eli-lillys-investigational-oral-pill-shows-weight-loss-benefits-with-lingering-side-effect-concerns">Eli Lilly&#8217;s Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns</a></li>
</ul>
Image via Shutterstock

Analyst Color

Analyst Ratings

Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern

WIIM

Novo Nordisk shares are trading lower after the company announced it will no longer be working with Hims & Hers Health and it will not provide it direct access to Wegovy via NovoCare Pharmacy.

Novo Nordisk Says Direct Access To Wegovy Will No Longer Be Available To Hims & Hers Health Via NovoCare Pharmacy

Novo Nordisk Terminates Collaboration With Hims & Hers Health, Direct Access To Wegovy Will No Longer Be Available To Hims & Hers Health, Inc. Via Novocare Pharmacy

<a href="https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916349">https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916349</a>

'In REACH Real-world Analysis, 23% Risk Reduction In A1C-adjusted 3-Point MACE Was Observed For Ozempic Injection Compared To Dulaglutide'

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$80.00</td>
<td>$26.6K</td>
<td>6.2K</td>
<td>4.8K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$100.00</td>
<td>$148.2K</td>
<td>5.5K</td>
<td>773</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$260.00</td>
<td>$50.1K</td>
<td>43</td>
<td>11</td>
</tr>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$300.00</td>
<td>$32.5K</td>
<td>1.6K</td>
<td>10</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$640.00</td>
<td>$86.9K</td>
<td>58</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bullish, expiring in 56 day(s) on August 15, 2025. This event was a transfer of 70 contract(s) at a $80.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $26.6K, with a price of $380.0 per contract. There were 6204 open contracts at this strike prior to today, and today 4845 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 210 day(s) on January 16, 2026. Parties traded 152 contract(s) at a $100.00 strike. The total cost received by the writing party (or parties) was $148.2K, with a price of $975.0 per contract. There were 5518 open contracts at this strike prior to today, and today 773 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bearish, expiring in 910 day(s) on December 17, 2027. This event was a transfer of 11 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $50.1K, with a price of $4555.0 per contract. There were 43 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold. 
• For MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we notice a call option trade that happens to be bearish, expiring in 119 day(s) on October 17, 2025. This event was a transfer of 10 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $32.5K, with a price of $3250.0 per contract. There were 1670 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a call option trade that happens to be neutral, is expiring today. Parties traded 10 contract(s) at a $640.00 strike. The total cost received by the writing party (or parties) was $86.9K, with a price of $8690.0 per contract. There were 58 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

MDGL

5 Health Care Stocks With Whale Alerts In Today's Session

Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) short percent of float has risen 21.95% since its last report. The company recently reported that it has 33.67 million shares sold short, which is 1.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.28 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Novo Nordisk Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750341618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novo Nordisk has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novo Nordisk's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Novo Nordisk's peer group average for short interest as a percentage of float is 4.03%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Novo Nordisk?

Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-<a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">induced weight loss</a>.
Tirzepatide is an active ingredient in Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) widely used Mounjaro and Zepbound for diabetes and weight loss, respectively.
The trial demonstrated that 30% of the total weight loss with tirzepatide alone was <a href="https://www.benzinga.com/pressreleases/25/06/b45991772/scholar-rock-reports-positive-phase-2-embraze-trial-results-demonstrating-statistically-significan" target="_blank" rel="noreferrer noopener">due to lean mass loss</a>.
Apitegromab therapy (10 mg/kg) with tripeptide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tripeptide alone, leading to higher-quality weight loss.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44359926/scholar-rock-stock-jumps-on-additional-data-from-pivotal-trial-of-muscular-dystrophy-treatment" rel="noreferrer noopener">Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment</a>
The study showed that 30.2% of the total weight loss with tirzepatide, the ingredient in Zepbound, was due to lean mass loss.
According to 24-week data, adding 10 mg/kg apitegromab therapy to the tripeptide regimen halved the proportion of lean mass lost to 14.6%.
The company described the apitegromab-tirzepatide combo as "higher quality of weight loss." Specifically, these patients lost 85% and 15% of their fat and lean mass, respectively, while the ratio for the&nbsp;tirzepatide-placebo cohort was 70% and 30%.
Regarding total weight loss, patients on apitegromab-tirzepatide saw their weight drop by 12.3% compared to 13.4% for those on tirzepatide-placebo.
Apitegromab with tirzepatide was generally well tolerated by participants.
Earlier in June, Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)&nbsp;released interim results from the ongoing Phase 2 COURAGE trial investigating combinations of&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide) (GLP-1&nbsp;receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">(anti-activin A) for obesity</a>.
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass.
Last week, Juvena Therapeutics Inc. announced global licensing and&nbsp;multi-target research collaboration&nbsp;with&nbsp;Eli Lilly. The two companies aim to develop and commercialize drug candidates that improve&nbsp;<a href="https://www.benzinga.com/news/health-care/25/06/45887444/eli-lilly-inks-pact-with-juvena-therapeutics-to-develop-muscle-boosting-drugs" target="_blank" rel="noreferrer noopener">muscle health and body composition</a>.
Price Action: SRRK stock is up 18% at $36.77 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45947852/eli-lilly-launches-flat-pricing-for-zepbound-capping-monthly-cost-at-499" target="_blank" rel="noreferrer noopener">Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499</a></li>
</ul>
Photo: Shutterstock

SRRK

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

Legal

Press Releases

Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion

Small Cap

Opinion

From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room

New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing

Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Novo Nordisk A/S (NVO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety

AVAI

PODD

TDOC

TNDM

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

BMO Capital

Cantor Fitzgerald

Argus Research

Morgan Stanley

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Comments

Novo Nordisk

Noticias

Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL